As attention shifts to what will replace the 2014 Pharmaceutical Price Regulation Scheme (PPRS), Leela Barham provides the first in a series of five features to look at whether the scheme has m
Leela Barham delves into the Department of Health’s accounts to see how contributions from the updated Pharmaceutical Price Regulation Scheme (PPRS) have affected its budget for the NHS since s
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
